Facts about an implantable contraceptive: memorandum from a WHO meeting.
This Memorandum reviews the results of research undertaken in animals and human subjects on the implantable contraceptive, Norplant, and where relevant, its components, levonorgestrel and Silastic. Results from clinical trials, including effectiveness and side-effects, are evaluated and service delivery aspects commented on. The Memorandum concludes with a statement regarding the use of Norplant as an option for long-term reversible contraception.
D000818:Animals; D003270:Contraceptive Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D004343:Drug Implants; D005260:Female; D005836:Genitalia, Female / Q000187:drug effects; D006801:Humans; D016912:Levonorgestrel; D009644:Norgestrel / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D012098:Reproduction / Q000187:drug effects; D012826:Silicone Elastomers / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity
D003270:Contraceptive Agents; D003277:Contraceptives, Oral, Combined; D004343:Drug Implants; D012826:Silicone Elastomers; D009644:Norgestrel; D016912:Levonorgestrel